 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || Clinical, Review, Journal: How to optimize the effectiveness and safety of Parkinson's disease therapy? - a systematic review of drugs interactions with food and dietary supplements. (Pubmed Central) - Jun 22, 2022
Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction with the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine oxidase B when administered in supratherapeutic doses. The level of presented evidence is low due to the poor studies design, their insufficient actuality, and missing data.
- | Journal: Drugs for Parkinson's disease. (Pubmed Central) - Mar 10, 2021
The level of presented evidence is low due to the poor studies design, their insufficient actuality, and missing data. No abstract available
- | amantadine / Generic mfg.
Review, Journal: Comparison chart: Drugs for Parkinson's disease. (Pubmed Central) - Mar 10, 2021
No abstract available No abstract available
- | Journal: Istradefylline (Nourianz) for Parkinson's disease. (Pubmed Central) - Feb 15, 2020
No abstract available No abstract available
- | Zelapar (selegiline orally disintegrating tablets) / Perrigo Company, Amarin, Bausch Health
Journal: Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). (Pubmed Central) - Nov 2, 2019
In addition, molecular dynamics results also revealed that acacetin 7-methyl ether formed a stable and strong complex with MAO-B. The selective inhibition of MAO-B suggests further investigations on acacetin 7-methyl as a potential new drug lead for the treatment of neurodegenerative disorders, including Parkinson's disease.
- ||| Zelapar (selegiline orally disintegrating tablets) / Perrigo Company, Bausch Health
Enrollment change, Adverse events: AtoZ: Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists (clinicaltrials.gov) - Oct 31, 2014
P4, N=77, Completed, Sponsor: Parkinson's Disease and Movement Disorder Center of Boca Raton
The selective inhibition of MAO-B suggests further investigations on acacetin 7-methyl as a potential new drug lead for the treatment of neurodegenerative disorders, including Parkinson's disease. N=60 --> 77